← back to search

Vasileios Askoxylakis

Servier (France) · FR
🔎 Find collaborators in Cancer Research · Oncology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer, Hypoxia, and Metabolism, HER2/EGFR in Cancer Research, Pancreatic and Hepatic Oncology Research, and Growth Hormone and Insulin-like Growth Factors.
h-index
31
citations
4,246
works
115
NIH funding
primary concept
Medicine
email

Recent publications

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
Nature Communications 2025cited by 31position: middledoi
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
OncoImmunology 2023cited by 25position: middledoi
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Journal for ImmunoTherapy of Cancer 2022cited by 152position: middledoi
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
Annals of Oncology 2020cited by 52position: middledoi
Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green
Proceedings of the National Academy of Sciences 2018cited by 681position: middledoi
Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood–tumor barrier disruption
Proceedings of the National Academy of Sciences 2018cited by 235position: middledoi
Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium
Nature Biomedical Engineering 2018cited by 197position: middledoi
A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.
Journal of Clinical Oncology 2018cited by 15position: lastdoi
CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer
Annals of Oncology 2018cited by 8position: lastdoi
Solid stress and elastic energy as measures of tumour mechanopathology
Nature Biomedical Engineering 2016cited by 432position: middledoi
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Proceedings of the National Academy of Sciences 2016cited by 354position: middledoi
Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis
Radiation Oncology 2016cited by 60position: firstdoi
Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy
JNCI Journal of the National Cancer Institute 2015cited by 130position: middledoi
Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.
PubMed 2015cited by 39position: middle
Screening of a Novel Peptide Targeting the Proteoglycan-Like Region of Human Carbonic Anhydrase IX
Molecular Imaging 2013cited by 21position: lastdoi
Peptide Arrays for Development of PDGFRβ Affine Molecules
Molecular Imaging and Biology 2013cited by 14position: lastdoi
Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial
Radiation Oncology 2012cited by 36position: firstdoi
Antitumor Effects of Proteasome Inhibition in Anaplastic Thyroid Carcinoma
Journal of Nuclear Medicine 2012cited by 36position: middledoi
Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta
Molecular Imaging and Biology 2012cited by 30position: firstdoi
Optimization of a Novel Peptide Ligand Targeting Human Carbonic Anhydrase IX
PLoS ONE 2012cited by 17position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Jürgen Debus · NYU Langone Health7 papers (2012–2016)Annette Altmann · German Cancer Research Center5 papers (2012–2013)Peter E. Huber · German Cancer Research Center5 papers (2012–2016)Dai Fukumura · Harvard University5 papers (2015–2018)Uwe Haberkorn · Heidelberg University4 papers (2012–2013)Meenal Datta · Tufts University4 papers (2016–2018)Uwe Haberkorn · German Cancer Research Center3 papers (2012–2015)Shoaib Rana · German Cancer Research Center3 papers (2012–2013)Giorgio Seano · Centre National de la Recherche Scientifique3 papers (2015–2018)Felix Nissen · Heidelberg University3 papers (2012–2013)Sergio Santillana · Solace Therapeutics (United States)3 papers (2018–2020)Annette Markert · Heidelberg University3 papers (2012–2012)J. Marc Pipas · GeoVax (United States)3 papers (2018–2020)Annabell Marr · Heidelberg University3 papers (2012–2013)Walter Mier · Heidelberg University3 papers (2012–2013)Hadi T. Nia · Boston University2 papers (2016–2018)Yves Boucher · Harvard University2 papers (2015–2016)Syed F. Zafar · Florida Cancer Specialists & Research Institute2 papers (2018–2020)Gino B. Ferraro · McGill University2 papers (2018–2018)Timothy P. Padera · Massachusetts Institute of Technology2 papers (2016–2018)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Cancer Research · Oncology →